Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus

Izmirly, Peter; Saxena, Amit; Buyon, Jill P.

doi:10.1097/bor.0000000000000414

Cited by 45 publications

(29 citation statements)

References 40 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Follow up with an ECG and an echocardiogram is recommended for those with first degree and second degree. It is important to note that up to 2% of infants develop atrioventricular blocks within the first month [9].…”

Section: Discussionmentioning

confidence: 99%

A Neonate With Annular Cutaneous Lesions

Vega

Duque

Don-Pedro

et al. 2020

Cureus

View full text Add to dashboard Cite

Neonatal lupus erythematosus is a rare disorder with a wide spectrum of clinical presentations. The disease can affect several systems, including the skin, heart, liver, and bone marrow. Thus, a recognition of its different presentations is vital for making a diagnosis. We describe the case of a neonate diagnosed with neonatal lupus, presenting with an acute onset of erythematous skin lesions as the sole manifestation. The patient's mother was healthy with no known medical history or relevant family history

show abstract

Section: Discussionmentioning

confidence: 99%

A Neonate With Annular Cutaneous Lesions

Vega

Duque

Don-Pedro

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…HCQ is evaluated in cardiac neonatal lupus model and it gives favorable results. The authors ascribe this effect due to its effects on diminishing an inflammatory component [38].…”

Section: Discussionmentioning

confidence: 99%

Impact of Hydroxychloroquine on Fructose-induced Metabolic Syndrome in Rats: Promising Protective Effect

Shata¹,

Naga²,

Elsawy³

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Hydroxychloroquine (HCQ) is used in the treatment of malaria and rheumatoid arthritis for a long time. Its effects on inflammation and immune modulation were noted. AIM: This study aims to investigate the effects of HCQ in fructose-induced metabolic syndrome and to explore its possible mechanisms. METHODS AND MATERIALS: Sixty male Sprague-Dawley rats were divided into Group I (negative control), Group II fed on high-fructose diet, and Group III fed on high fructose and subdivided into Group III-a (HCQ 50 mg/kg), Group III-b (HCQ 100 mg/kg), Group III-c (HCQ 200 mg/kg), and Group III-d (metformin 100 mg/kg). Body weight, blood glucose, liver enzymes, and lipid profile were measured. Insulin level, homeostatic model assessment (HOMA), soluble-intercellular adhesion molecule, and vascular cell adhesion molecule were assayed. Tumor necrosis factor (TNF)-α, adipokines (leptin, resistin, and adiponectin), and histological examination of pancreas were assessed. RESULTS: HCQ induces good effects on lipid profile and improves significantly HOMA, endothelial stress markers, and adiponectin, and reduces leptin and TNF-α levels. In addition, significant improvement in structural changes was noted in pancreas with different doses of HCQ. CONCLUSION: Favorable effects of HCQ in fructose-induced metabolic syndrome are promising and can be used early in those at risk of diabetes.

show abstract

“…The end result is transdifferentiation of fibroblasts into myofibroblasts, leading to scar formation replacing the AV node. Recent studies position Siglec‐1 (surface protein sialic acid‐binding Ig‐like lectin 1) positive macrophages as integral to the process 59,60 …”

Section: Maternal Sle In the Second And Third Trimestermentioning

confidence: 99%

A review of fetal and neonatal consequences of maternal systemic lupus erythematosus

et al. 2020

Self Cite

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) primarily affects women of childbearing age and is commonly seen in pregnancy. The physiologic and immunologic changes of pregnancy may alter the course of SLE and impact maternal, fetal, and neonatal health. Multidisciplinary counseling before and during pregnancy from rheumatology, maternal fetal medicine, obstetrics, and pediatric cardiology is critical. Transplacental passage of autoantibodies, present in about 40% of women with SLE, can result in neonatal lupus (NL). NL can consist of usually permanent cardiac manifestations, including conduction system and myocardial disease, as well as transient cutaneous, hematologic, and hepatic manifestations. Additionally, women with SLE are more likely to develop adverse pregnancy outcomes such as preeclampsia, fetal growth restriction, and preterm birth, perhaps due to an underlying effect on placentation. This review describes the impact of SLE on maternal and fetal health by trimester, beginning with prepregnancy optimization of maternal health. This is followed by a discussion of NL and the current understanding of the epidemiology and pathophysiology of anti‐Ro/La mediated cardiac disease, as well as screening, treatment, and methods for prevention. Finally discussed is the known increase in preeclampsia and fetal growth issues in women with SLE that can lead to iatrogenic preterm delivery.

show abstract

Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus

Cited by 45 publications

References 40 publications

A Neonate With Annular Cutaneous Lesions

A Neonate With Annular Cutaneous Lesions

Impact of Hydroxychloroquine on Fructose-induced Metabolic Syndrome in Rats: Promising Protective Effect

A review of fetal and neonatal consequences of maternal systemic lupus erythematosus

Contact Info

Product

Resources

About